Retrospective analysis of low-dose interleukin-2 therapy on chronic autoimmune thyroid disease with concurrent systemic lupus erythematosus

References

• Antonelli A, Ferrari SM, Corrado A, et al. Autoimmune thyroid disorders. Autoimmun Rev. 2015;14(2):1–9. doi:10.1016/j.autrev.2014.10.016.
   PubMed Web of Science ®Google Scholar
• McLeod DS, Cooper DS. The incidence and prevalence of thyroid autoimmunity. Endocrine. 2012;42(2):252–265. doi:10.1007/s12020-012-9703-2.
   PubMed Web of Science ®Google Scholar
• Pearce SH, Leech NJ. Toward precise forecasting of autoimmune endocrinopathy. J Clin Endocrinol Metab. 2004;89(2):544–547. doi:10.1210/jc.2003-032142.
   PubMed Web of Science ®Google Scholar
• Lee HJ, Li CW, Hammerstad SS, et al. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J Autoimmun. 2015;64:82–90. doi:10.1016/j.jaut.2015.07.009.
   PubMed Web of Science ®Google Scholar
• Benvenga S, Elia G, Ragusa F, et al. Endocrine disruptors and thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab. 2020;34(1):101377. doi:10.1016/j.beem.2020.101377.
   PubMed Web of Science ®Google Scholar
• Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379(9821):1142–1154. doi:10.1016/s0140-6736(11)60276-6.
   PubMed Web of Science ®Google Scholar
• Biondi B, Cooper DS. Subclinical hyperthyroidism. N Engl J Med. 2018;378(25):2411–2419. doi:10.1056/NEJMcp1709318.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, Elia G, et al. Thyroid autoimmune disorders and cancer. Semin Cancer Biol. 2020;64:135–146. doi:10.1016/j.semcancer.2019.05.019.
   PubMed Web of Science ®Google Scholar
• Ralli M, Angeletti D, Fiore M, et al. Hashimoto’s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649. doi:10.1016/j.autrev.2020.102649.
   PubMed Web of Science ®Google Scholar
• Bartalena L. Diagnosis and management of graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724–734. doi:10.1038/nrendo.2013.193.
   PubMed Web of Science ®Google Scholar
• McLachlan SM, Rapoport B. Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity. Endocr Rev. 2014;35(1):59–105. doi:10.1210/er.2013-1055.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hegedüs L. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565. doi:10.1056/NEJMra1510030.
   PubMed Web of Science ®Google Scholar
• Hu Y, Zhang L, Chen H, et al. Analysis of regulatory T cell subsets and their expression of helios and PD-1 in patients with hashimoto thyroiditis. Int J Endocrinol. 2019;2019:5368473. doi:10.1155/2019/5368473.
   PubMed Web of Science ®Google Scholar
• Sacks D, Baxter B, Campbell BCV, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018;13:612–632. doi:10.1177/1747493018778713.
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133. doi:10.1089/thy.2015.0020.
   PubMed Web of Science ®Google Scholar
• Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): national health and nutrition examination survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–499. doi:10.1210/jcem.87.2.8182.
   PubMed Web of Science ®Google Scholar
• Khan FA, Al-Jameil N, Khan MF, et al. Thyroid dysfunction: an autoimmune aspect. Int J Clin Exp Med. 2015;8:6677–6681.
   PubMed Web of Science ®Google Scholar
• Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the whickham survey. Clin Endocrinol (Oxf). 1995;43(1):55–68. doi:10.1111/j.1365-2265.1995.tb01894.x.
   PubMed Web of Science ®Google Scholar
• Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. Jama. 2019;322(2):153–160. doi:10.1001/jama.2019.9052.
   PubMed Web of Science ®Google Scholar
• Soh SB, Aw TC. Laboratory testing in thyroid Conditions - Pitfalls and clinical utility. Ann Lab Med. 2019;39(1):3–14. doi:10.3343/alm.2019.39.1.3.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Voell M, Rahlff I, et al. Long-term follow-up of antithyroid peroxidase antibodies in patients with chronic autoimmune thyroiditis (hashimoto’s thyroiditis) treated with levothyroxine. Thyroid. 2008;18(7):755–760. doi:10.1089/thy.2008.0008.
   PubMed Web of Science ®Google Scholar
• El Fassi D, Banga JP, Gilbert JA, et al. Treatment of graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin Immunol. 2009;130(3):252–258. doi:10.1016/j.clim.2008.09.007.
   PubMed Web of Science ®Google Scholar
• Shao S, Yu X, Shen L. Autoimmune thyroid diseases and Th17/treg lymphocytes. Life Sci. 2018;192:160–165. doi:10.1016/j.lfs.2017.11.026.
   PubMed Web of Science ®Google Scholar
• Li C, Yuan J, Zhu YF, et al. Imbalance of Th17/treg in different subtypes of autoimmune thyroid diseases. Cell Physiol Biochem. 2016;40(1–2):245–252. doi:10.1159/000452541.
   PubMedGoogle Scholar
• Xue H, Yu X, Ma L, et al. The possible role of CD4+CD25(high)Foxp3+/CD4+IL-17A+ cell imbalance in the autoimmunity of patients with hashimoto thyroiditis. Endocrine. 2015;50(3):665–673. doi:10.1007/s12020-015-0569-y.
   PubMed Web of Science ®Google Scholar
• Bossowski A, Moniuszko M, Dąbrowska M, et al. Lower proportions of CD4 + CD25(high) and CD4 + FoxP3, but not CD4 + CD25 + CD127(low) FoxP3+ T cell levels in children with autoimmune thyroid diseases. Autoimmunity. 2013;46(3):222–230. doi:10.3109/08916934.2012.751981.
   PubMed Web of Science ®Google Scholar
• Wei WZ, Morris GP, Kong YC. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother. 2004;53(2):73–78. doi:10.1007/s00262-003-0444-1.
   PubMed Web of Science ®Google Scholar
• Verginis P, Li HS, Carayanniotis G. Tolerogenic semimature dendritic cells suppress experimental autoimmune thyroiditis by activation of thyroglobulin-specific CD4 + CD25+ T cells. J Immunol. 2005;174(11):7433–7439. doi:10.4049/jimmunol.174.11.7433.
   PubMed Web of Science ®Google Scholar
• Marazuela M, García-López MA, Figueroa-Vega N, et al. Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab. 2006;91(9):3639–3646. doi:10.1210/jc.2005-2337.
   PubMed Web of Science ®Google Scholar
• Zha B, Huang X, Lin J, et al. Distribution of lymphocyte subpopulations in thyroid glands of human autoimmune thyroid disease. J Clin Lab Anal. 2014;28(3):249–254. doi:10.1002/jcla.21674.
   PubMed Web of Science ®Google Scholar
• Glick AB, Wodzinski A, Fu P, et al. Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid. 2013;23(7):871–878. doi:10.1089/thy.2012.0514.
   PubMed Web of Science ®Google Scholar
• Zhao J, Chen Y, Zhao Q, et al. Increased circulating Tfh17 and PD-1(+)tfh cells are associated with autoantibodies in hashimoto’s thyroiditis. Autoimmunity. 2018;51(7):352–359. doi:10.1080/08916934.2018.1516761.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ren M, Zeng H, et al. Elevated follicular helper T cells and expression of IL-21 in thyroid tissues are involved in the pathogenesis of graves’ disease. Immunol Res. 2015;62(2):163–174. doi:10.1007/s12026-015-8647-z.
   PubMed Web of Science ®Google Scholar
• Abbas AK, Trotta E, D RS, et al. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol. 2018;3(25):1–8. doi:10.1126/sciimmunol.aat1482.
   Web of Science ®Google Scholar
• He J, Zhang X, Wei Y, et al. Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus. Nat Med. 2016;22(9):991–993. doi:10.1038/nm.4148.
   PubMed Web of Science ®Google Scholar
• He J, Zhang R, Shao M, et al. Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2020;79(1):141–149. doi:10.1136/annrheumdis-2019-215396.
   PubMed Web of Science ®Google Scholar
• Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis. 2019;78(2):209–217. doi:10.1136/annrheumdis-2018-214229.
   PubMed Web of Science ®Google Scholar
• Miao M, Li Y, Huang B, et al. Treatment of active idiopathic inflammatory myopathies by Low-Dose interleukin-2: a prospective cohort pilot study. Rheumatol Ther. 2021;8(2):835–847. doi:10.1007/s40744-021-00301-3.
   PubMed Web of Science ®Google Scholar
• Vitale G, Lupoli G, Guarrasi R, et al. Interleukin-2 and lanreotide in the treatment of medullary thyroid cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2013;98(10):E1567–1574. doi:10.1210/jc.2013-1443.
   PubMed Web of Science ®Google Scholar
• Martinez Quintero B, Yazbeck C, Sweeney LB. Thyroiditis: evaluation and treatment. Am Fam Physician. 2021;104:609–617.
   PubMed Web of Science ®Google Scholar
• Eisenstein Z, Engelsman E, Weiss M, et al. Production of and response to interleukin-2 in graves’ disease. J Clin Immunol. 1988;8(5):349–355. doi:10.1007/bf00917150.
   PubMed Web of Science ®Google Scholar